SRR1414424
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- KRAS_SIGNALING_DN+0.451
- TNFA_SIGNALING_VIA_NFKB+0.443
- INFLAMMATORY_RESPONSE+0.433
- ANGIOGENESIS+0.425
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.387
- ALLOGRAFT_REJECTION+0.379
- IL6_JAK_STAT3_SIGNALING+0.361
- KRAS_SIGNALING_UP+0.341
- APICAL_SURFACE+0.316
- COAGULATION+0.288
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.664
- MYC_TARGETS_V1-0.620
- DNA_REPAIR-0.574
- MYC_TARGETS_V2-0.479
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.478
- PROTEIN_SECRETION-0.474
- ADIPOGENESIS-0.463
- UNFOLDED_PROTEIN_RESPONSE-0.440
- E2F_TARGETS-0.420
- FATTY_ACID_METABOLISM-0.415
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR1362464 | GTEX | — | 0.957 |
| 2 | SRR1500800 | GTEX | — | 0.955 |
| 3 | SRR1467294 | GTEX | — | 0.953 |
| 4 | SRR1354577 | GTEX | — | 0.953 |
| 5 | BS_YG0A13JH | pilocytic astrocytoma | — | 0.952 |
| 6 | MDT-AP-1108 | Med | Medulloblastoma | 0.951 |
| 7 | SRR1358561 | GTEX | — | 0.951 |
| 8 | SRR602271 | GTEX | — | 0.946 |
| 9 | SRR1322456 | GTEX | — | 0.943 |
| 10 | SRR1352706 | GTEX | — | 0.943 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 24 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| KRAS_SIGNALING_DN | 0.451 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.443 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.433 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.425 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.387 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.379 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.361 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.341 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.316 | Temsirolimus | — uncovered |
| COAGULATION | 0.288 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.244 | Inavolisib | — uncovered |
| COMPLEMENT | 0.242 | Inavolisib | — uncovered |
| MYOGENESIS | 0.227 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.224 | Cobimetinib | — uncovered |
| SPERMATOGENESIS | 0.189 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.184 | Idelalisib | — uncovered |
| HYPOXIA | 0.166 | Idelalisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.161 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.148 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.143 | Inavolisib | — uncovered |